Bioscience advocates call for biosimilar support

11/2/2009 | (Wilmington)

Delaware BioScience Association President Bob Dayton and BIO President and CEO Jim Greenwood in this letter to the editor call on Delaware's lawmakers to protect consumer safety and ensure innovation of biosimilars as Congress works on health care reform legislation. Creating an avenue for regulatory approval will ensure biosimilars "are tested for safety while expanding access, lowering costs through expanded competition and providing incentives for biotech companies to continue innovating," they write.

View Full Article in: (Wilmington)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC